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Introduction
FGF receptors (FGFRs) are cell surface receptor tyrosine ki-
nases (RTKs) that, upon binding of FGFs, undergo dimerization 
and trans-phosphorylation (Beenken and Mohammadi, 2009), 
which generates multiple docking sites for several adaptor and 
effector proteins, thus resulting in the activation of various sig-
naling pathways (Eswarakumar et al., 2005; Furdui et al., 2006). 
Typical effectors of FGFR activity are Shc and FGFR substrate-
2 (FRS-2) that, by recruiting the Grb2–SOS complex, induce 
the activation of the Ras–Raf–Erk1/2 pathway (Eswarakumar   
et al., 2005). As for most RTKs, ligand binding induces FGFR 
internalization and Cbl-mediated ubiquitination followed by ly-
sosomal degradation (Wong et al., 2002).
In  addition  to  heparan  sulfate  proteoglycans  (Yayon   
et al., 1991), FGF signaling can also be modulated by several 
membrane proteins (Polanska et al., 2009), including cell ad-
hesion molecules (CAMs) of the cadherin and immunoglobu-
lin (Ig-CAMs) superfamilies (Cavallaro and Christofori, 2004). 
Among the Ig-CAMs that functionally interact with FGFR, 
the best characterized is neural CAM (NCAM), a cell surface 
glycoprotein whose extracellular portion contains five Ig-like 
domains and two FNIII (fibronectin type III) repeats (Hinsby 
et al., 2004). In the central nervous system, NCAM enhances 
intercellular adhesion, axonal growth, and neuronal migra-
tion through both homophilic NCAM-mediated cell–cell ad-
hesion  and  heterophilic  interactions  with  other  membrane 
proteins or extracellular matrix components (Hinsby et al., 
2004).  After  the  pioneering  work  that  implicated  NCAM- 
mediated FGFR signaling in neurite outgrowth (Williams et al., 
1994), the NCAM–FGFR association has been demonstrated 
in several cell types, including nonneural cells (Cavallaro   
et al., 2001; Kos and Chin, 2002; Sanchez-Heras et al., 2006; 
Francavilla et al., 2007). Recently, NCAM-derived peptides or 
protein domains have been reported to interact with FGFR1 
and FGFR2 (Kiselyov et al., 2003; Christensen et al., 2006) 
and to modulate various FGFR-mediated neuronal functions 
(Hansen et al., 2008). Nevertheless, the biological significance 
  N
eural cell adhesion molecule (NCAM) associates 
with  fibroblast  growth  factor  (FGF)  receptor-1 
(FGFR1). However, the biological significance of 
this interaction remains largely elusive. In this study, we 
show that NCAM induces a specific, FGFR1-mediated cel-
lular response that is remarkably different from that elic-
ited by FGF-2. In contrast to FGF-induced degradation of 
endocytic FGFR1, NCAM promotes the stabilization of the 
receptor, which is recycled to the cell surface in a Rab11- 
and Src-dependent manner. In turn, FGFR1 recycling is 
required for NCAM-induced sustained activation of vari-
ous effectors. Furthermore, NCAM, but not FGF-2, pro-
motes cell migration, and this response depends on FGFR1 
recycling and sustained Src activation. Our results impli-
cate NCAM as a nonconventional ligand for FGFR1 that 
exerts a peculiar control on the intracellular trafficking of 
the receptor, resulting in a specific cellular response. Be-
sides introducing a further level of complexity in the regu-
lation of FGFR1 function, our findings highlight the link of 
FGFR recycling with sustained signaling and cell migra-
tion and the critical role of these events in dictating the 
cellular response evoked by receptor activation.
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was  able  to  recapitulate  the  FGFR-dependent  function  of 
membrane-associated NCAM.
These observations validated NCAM-Fc as a suitable tool 
to study the impact of NCAM on FGFR function, and the physio-
logical relevance of this approach is further supported by the 
notion that NCAM also occurs as a soluble protein naturally re-
leased by various cell types in vivo (Secher, 2008). However, 
the ectodomain of NCAM contains several modules that engage 
in both homophilic (i.e., NCAM–NCAM) and heterophilic 
interactions with various cell surface and extracellular matrix 
molecules (Nielsen et al., 2008). Thus, to focus specifically on 
the effect of NCAM binding to FGFR, the experiments with 
NCAM-Fc were complemented with the NCAM-derived FGL 
peptide, which mimics the binding to and activation of FGFR1 
(Kiselyov et al., 2003). Indeed, both in cell matrix adhesion 
(Fig. S1 E) and in the assays described in the following para-
graphs, we obtained convincing evidence that FGL recapitulates 
the FGFR-dependent function of NCAM-Fc.
NCAM and FGF stimulate different FGFR1-
mediated pathways
Membrane-associated NCAM inhibits FGF signaling in dif-
ferent cell types (Francavilla et al., 2007). Therefore, to com-
pare the impact of NCAM on FGFR function with that of FGF, 
we selected the HeLa epithelial cell line, which does not ex-
press NCAM (Fig. S1 F). Furthermore, HeLa cells express all 
FGFR family members (Fig. 1 A) and are amenable to the bio-
chemical and imaging approaches that were undertaken to this 
purpose. Finally, we verified that the ectopic expression of 
membrane-associated NCAM in HeLa cells did not affect the 
ability of soluble NCAM fragments to induce FGFR-mediated 
signaling (Fig. S1 F), further supporting the choice of this cell 
line as a model system suitable to investigating the effect of 
NCAM versus FGF.
When HeLa cells were treated for 10 min with FGF-2, 
NCAM-Fc, or FGL, each of these ligands stimulated the phos-
phorylation of FGFR1 to a similar extent (Fig. 1 A). In contrast, 
none of the ligands stimulated the phosphorylation of FGFR2 or 
FGFR3, suggesting that NCAM, similar to FGF-2 (Itoh and 
Ornitz, 2004), does not activate the epithelial isoforms of these 
FGFR family members. FGFR4 underwent phosphorylation in 
response to FGF-2, but not to FGL or NCAM-Fc, thus indicat-
ing that NCAM-derived ligands selectively induced the activa-
tion of FGFR1. The stimulation of HeLa cells with FGF-2, 
FGL, or NCAM-Fc led to the activation of FRS-2 and PLC-, 
two  classical  FGFR  substrates  (Eswarakumar  et  al.,  2005), 
which is an effect abolished by PD173074 (Fig. 1 B). FGF-2 in-
duced the phosphorylation of Shc adaptor proteins, whereas no 
effect was observed with either NCAM-Fc or FGL (Fig. 1 B). 
Non-RTKs of the Src family have been implicated in NCAM 
signaling (Williams et al., 1994; Kiryushko et al., 2006), and, 
indeed, the treatment of HeLa cells with NCAM-Fc or FGL 
but not with FGF-2 induced FGFR-dependent Src activation 
(Fig. 1 B). However, FGF-2 did induce Src phosphorylation in 
NIH-3T3 cells (unpublished data), thus pointing to cell type–
specific activities of this growth factor (Dailey et al., 2005). Finally, 
the activation of Erk1/2 was induced by FGF-2, NCAM-Fc, and 
of FGFR activation by NCAM has remained largely elusive, 
especially in nonneural cell types.
In this study, we have investigated the outcome of NCAM–
FGFR interplay in fibroblasts and epithelial cells. To this goal, 
we used soluble versions of NCAM, which enabled us to per-
form a direct comparison with FGF, the classical FGFR ligand 
that acts as a soluble growth factor. Our data show that (a) 
NCAM is a novel, noncanonical ligand for FGFR1 and induces 
a specific set of FGFR-dependent biochemical events, leading 
to cell migration; (b) soluble NCAM stimulates FGFR1 signal-
ing in the absence of cell surface NCAM; (c) NCAM induces 
the internalization of FGFR1 and, unlike FGF, promotes its re-
cycling to the cell surface, resulting in sustained signaling; and 
(d) NCAM stimulates cell migration, and this effect requires 
FGFR1 recycling. These data provide novel insights into the 
regulation and function of FGFR.
Results
Soluble, NCAM-derived fragments mimic 
cell surface NCAM in activating FGFR
To gain insights into the functional outcome of the NCAM–
FGFR interplay in nonneuronal cell types, we asked whether 
NCAM and FGFs, the classical FGFR ligands, elicit the same 
cellular response downstream of FGFR. We reasoned that, for a 
direct  comparison  with  FGF,  NCAM  must  be  presented  to 
FGFR as a soluble ligand rather than as a membrane protein. 
However, in most cases, NCAM occurs as a cell surface mole-
cule,  and  therefore,  we  initially  verified  whether  soluble 
NCAM-derived  molecules  recapitulated  the  FGFR-mediated 
function of membrane-associated NCAM.
First,  by  using  the  whole  ectodomains  of  NCAM  and 
FGFR1 in surface plasmon resonance and solid phase–binding 
assays (Fig. S1, A and B), we confirmed and extended previous 
data  on  the  binding  of  recombinant  or  synthetic  fragments   
of  NCAM  to  FGFR1  and  FGFR2  (Kiselyov  et  al.,  2003; 
Christensen et al., 2006). We previously reported that the recon-
stitution of pancreatic -tumor cells from NCAM knockout mice 
with full-length NCAM rescues both cell matrix adhesion and 
neurite outgrowth but only in the presence of an intact FGFR-
mediated  signaling,  thus  implicating  an  interplay  between 
NCAM and FGFR (Cavallaro et al., 2001). The treatment of 
NCAM-deficient -tumor cells with soluble NCAM-Fc, con-
sisting of the extracellular portion of NCAM fused to the Fc 
fragment of IgG, rescued both cell matrix adhesion (Fig. S1 C) 
and neurite outgrowth (not depicted). In contrast, no effect was 
observed with an NCAM-Fc version deleted of the second FNIII 
repeat (FN2-Fc), which is where the FGFR-binding motif is 
located (Kiselyov et al., 2003). Very similar results were ob-
tained on mouse fibroblast L cells, which express no endoge-
nous NCAM (Cavallaro et al., 2001; Francavilla et al., 2007). 
On one hand, the forced expression of trans-membrane NCAM 
stimulated matrix adhesion of L cells, an effect that was abol-
ished by the FGFR inhibitor PD173074 (Fig. S1 D). On the 
other hand, soluble NCAM-Fc promoted matrix adhesion of 
L cells via FGFR signaling, whereas FN2-Fc had no effect 
(Fig. S1 E). Thus, a soluble version of NCAM’s ectodomain 1103 NCAM induces cell migration via FGFR1 recycling • Francavilla et al.
which was no longer detectable after longer treatments, con-
firming and extending the data shown in Fig. 1 A. A prolonged 
phosphorylation was instead observed for Shc and Erk1/2 
(Fig. 2, left). In contrast to FGF-2, both FGL (Fig. 2, middle) 
and NCAM-Fc (Fig. 2, right) induced sustained phosphoryla-
tion of FRS-2, Akt, and Src, whereas no phosphorylation of 
Shc was detected. Instead, Erk1/2 activation occurred in a tran-
sient manner, declining after 1 h of treatment (Fig. 2, middle 
and right). Therefore, the interaction of NCAM or FGF with 
FGFR induced the activation of signaling cascades with remark-
ably different kinetics, with NCAM stimulating the sustained 
activation of the FGFR effectors FRS-2, Src, and Akt and tran-
sient activation of Erk1/2.
FGFR1 is stabilized and recycled to the cell 
surface upon NCAM stimulation
To verify whether the sustained activation of FGFR effectors 
upon NCAM-mediated stimulation depended on the intracellu-
lar fate of FGFR1, we used imaging technologies. Because HeLa 
cells express only a modest amount of endogenous FGFR1, we 
transfected them with HA-tagged FGFR1. In agreement with 
previous data (Zhang et al., 2001), ectopically expressed HA-
FGFR1 was not constitutively active and was responsive to FGF 
or  NCAM  stimulation  (unpublished  data).  We  applied  an   
immunofluorescence-based method that allowed us to monitor 
receptor internalization, degradation, and recycling (see Materials 
and methods). In cells treated with FGF-2, NCAM-Fc, or FGL 
for ≤60 min, HA-FGFR1 gradually disappeared from the cell 
surface (Fig. 3 A, left) and accumulated in the cytosol (Fig. 3 A, 
FGL in an FGFR-dependent manner, as demonstrated by the 
use of PD173074 (Fig. 1 B) or by the cell transfection with 
dominant-negative (dn) FGFR1 (Fig. S2 A). However, the under-
lying mechanisms were different because FGF-induced acti-
vation of Erk1/2 was mediated by Ras, which instead was not 
involved  downstream  of  NCAM-derived  ligands  (Fig.  1  C). 
Rather, the phosphorylation of Erk1/2 stimulated by NCAM-Fc 
and FGL required Src signaling because it was abolished by two 
distinct Src inhibitors, PP1 (Fig. 1 D) and SU6656 (Fig. S2 C), 
as well as by the forced expression of dn-Src (Fig. S2 D). In 
contrast, Src inhibition did not affect FGF-2–induced Erk1/2 
activation (Fig. 1 D; and Fig. S2, C and D). The dichotomy be-
tween NCAM and FGF signaling was also confirmed in L cells 
(Fig. S2, E–H), implying that it is not restricted to a single-cell 
type. Overall, these findings indicated that NCAM acts as a 
noncanonical ligand for FGFR in different cell types and in-
duces a set of FGFR-dependent signaling events distinct from 
that elicited by FGF.
NCAM induces sustained activation of 
FGFR effectors
We investigated the kinetics of FGFR signaling upon stimula-
tion of HeLa cells with FGF-2, NCAM-Fc, or FGL for different 
time periods. As shown in Fig. 2 (left), FGF-2 induced a tran-
sient activation of FRS-2 that declined after 30 min. Weak 
phosphorylation  of  Akt,  another  classical  FGFR  effector   
(Eswarakumar et al., 2005), was observed at 5 min but became 
undetectable at later time points. Immunoblotting for phospho-
Src showed a very weak band after 5 min of FGF-2 stimulation, 
Figure  1.  NCAM  and  FGF  activate  distinct 
FGFR-mediated  signaling  pathways.  (A)  Cell 
lysates (5 mg) from HeLa cells stimulated for 
10 min with FGF-2, FGL, or NCAM-Fc were 
immunoprecipitated  (IP)  with  control  IgG  or 
antibodies  against  individual  FGFR  types 
(FGFR1–4) and immunoblotted for phospho-
tyrosine (top) and for the corresponding FGFR 
types (bottom). (B, top) Equal loading for phos-
pho–PLC- was verified by immunoblotting for 
vinculin. (B–D) HeLa cells were stimulated for 
10 min with FGF-2, FGL, or NCAM-Fc with or 
without a pretreatment with PD173074 (B) or 
PP1 (D). (C) Cells were transfected with dn-Ras 
or an empty vector before the stimulation (see 
Fig. S2 B for the expression of dn-Ras). Cell ly-
sates were immunoblotted for phospho–PLC-, 
phospho–FRS-2, phospho-Shc, phospho-Src, 
and  phospho-Erk1/2  followed  by  immuno-
blotting for total PLC-, FRS-2, Shc, Src, and 
Erk1/2 as indicated.JCB • VOLUME 187 • NUMBER 7 • 2009   1104
readily detected the Cbl–FRS-2 complex in FGF-2–stimulated 
HeLa cells. Instead, cell treatment with FGL did not induce any 
association between Cbl and FRS-2 (Fig. 4 B). Thus, unlike 
FGF-2, NCAM stimulation of FGFR1 does not result in Cbl-
mediated receptor ubiquitination, likely accounting for the sta-
bilization of the receptor itself.
A clear indication of the cellular fate of stabilized FGFR1 
came from the immunofluorescence analysis of HA-FGFR1–
transfected HeLa cells (Fig. 3 A). At 2 and 4 h, neither surface 
nor cytosolic HA-FGFR1 was detected in FGF-2–treated cells, 
which is consistent with FGF-induced degradation of FGFR. In 
contrast, massive recycling of HA-FGFR1 to the cell surface 
occurred in cells stimulated with FGL or NCAM-Fc (Fig. 3 A, 
left). The quantification of the immunofluorescence results con-
firmed that both NCAM and FGF-2 promote the internalization 
of FGFR1 (Fig. S3 B, middle), but receptor recycling is only 
observed upon NCAM stimulation (Fig. S3 B, bottom). The 
dramatic  decrease  in  overall  HA-FGFR1  signal  in  FGF-2–
treated cells (Fig. S3 B, top) is consistent with receptor degrada-
tion. We also used a modified version of the biochemical method 
used for the internalization assay (see Materials and methods) 
to investigate the fate of endogenous FGFR1 after cell stimula-
tion. This technique confirmed that NCAM stimulation results 
in FGFR1 stabilization and recycling to the cell surface as op-
posed to FGF-induced degradation of the receptor (Fig. 3 C). 
The apparent delay in FGFR1 degradation observed in immuno-
fluorescence-based  as  compared  with  biochemical  assays  is 
likely caused by the antibody prebound to FGFR1 (see Materi-
als and methods). Indeed, when we performed the biochemical 
assay in the presence of the antibody, both FGF-induced degra-
dation and FGL-dependent recycling of FGFR1 were delayed 
(Fig. S3 C). The differential fate of internalized FGFR1 upon 
stimulation with FGF versus NCAM was further confirmed by 
right). At 30 min, both surface and cytosolic staining for HA-
FGFR1 were observed, suggesting that the receptor was not 
completely internalized at this time point. Instead, HA-FGFR1 
was mostly detected in the cytosol upon 60-min stimulation 
(Fig. 3 A, right). These results were further validated by bio-
chemical assays aimed at measuring the internalization of 
endogenously expressed FGFR1, an approach that revealed   
a comparable internalization rate between FGF-2 and FGL 
(Fig. S3 A). Therefore, the difference in the duration of FGFR1 
signaling downstream of NCAM versus FGF is not the result of 
different kinetics of receptor endocytosis. Several RTKs, after 
ligand-induced internalization, enter the degradative pathway, 
a  key  mechanism  underlying  signal  attenuation  (Dikic  and 
Giordano, 2003). To verify whether endogenous FGFR1 was de-
graded upon FGF versus NCAM stimulation, HeLa cells were 
treated with FGF-2, NCAM-Fc, or FGL for increasing time 
periods. The treatment was performed in the presence of cyclo-
heximide to minimize the contribution of newly synthesized 
FGFR1. In agreement with previous observations (Haugsten 
et al., 2005), nearly complete loss of FGFR1 was observed be-
tween 1 and 2 h of FGF stimulation. In contrast, cells stimulated 
with FGL or NCAM-Fc exhibited remarkable levels of FGFR1 
at all time points, with the receptor remaining well detectable 
even after 8 h of treatment (Fig. 3 B). As a possible mechanism 
accounting for NCAM-dependent stabilization of FGFR1, we 
verified whether NCAM and FGF exert a differential control on 
the degradation of the receptor. Because FGFR1 degradation is 
driven by Cbl-mediated ubiquitination (Wong et al., 2002), we 
investigated  this  pathway  in  HA-FGFR1–transfected  HeLa 
cells. Our results revealed that, in sharp contrast to FGF-2, FGL 
did not induce HA-FGFR1 ubiquitination (Fig. 4 A). The asso-
ciation of Cbl with FRS-2 is a prerequisite for FGF-induced 
ubiquitination of FGFR1 (Wong et al., 2002), and indeed, we 
Figure 2.  NCAM induces sustained signaling. 
Lysates from HeLa cells stimulated for the indi-
cated time intervals with FGF-2 (left), FGL (mid-
dle), or NCAM-Fc (right) were immunoblotted for 
phospho–FRS-2,  phospho-Akt,  phospho-Src,   
phospho-Shc, or phospho-Erk1/2 followed by 
immunoblotting for total FRS-2, Akt, Src, Shc, 
or total Erk1/2 as indicated.1105 NCAM induces cell migration via FGFR1 recycling • Francavilla et al.
recycling (Jones et al., 2006). In cells stimulated with FGL or 
NCAM-Fc, HA-FGFR1 showed extensive colocalization with 
Rab11, whereas no costaining was observed in FGF-2–treated 
cells (Fig. 5 D).
Collectively,  these  results  indicate  that  FGFR1  enters 
early endosomes upon both FGF-2 and NCAM stimulation but 
is then sorted to divergent routes. In FGF-2–stimulated cells, 
FGFR1 is targeted for lysosomal degradation, whereas NCAM 
promotes the stabilization of FGFR1 followed by its recycling 
to the cell surface via Rab11-positive vesicles.
As a possible mechanism accounting for FGFR1 recy-
cling in NCAM-stimulated cells, we focused on Src activity 
based on the considerations that (a) sustained Src activation was 
an NCAM-specific effect (Figs. 1 and 2) and that (b) Src has 
been implicated in the trafficking of FGFR1 (Sandilands et al., 
2007). Thus, HA-FGFR1–transfected HeLa cells were pretreated 
with either PP1 or SU6656 before monitor receptor trafficking 
in FGF-2– or NCAM-stimulated cells. Receptor recycling was 
colocalization studies using EEA1 (Mu et al., 1995), LAMP-2 
(Chen et al., 1985), and transferrin (Tf; Hopkins, 1983) as mark-
ers of early endosomes, lysosomes, and recycling vesicles, re-
spectively. After  a  10-min  stimulation  with  either  FGF-2  or 
NCAM-derived ligands, HA-FGFR1 was localized in early endo-
somes (Fig. 5 A), thus confirming that both FGF and NCAM 
promote FGFR endocytosis. Cell stimulation for 60 min with 
FGF-2, but not FGL or NCAM-Fc, resulted in HA-FGFR1 ac-
cumulation in lysosomes (Fig. 5 B), thus supporting the notion 
that FGF promotes lysosome-mediated degradation of FGFR1 
(Haugsten et al., 2005), as also confirmed by our immunoblot-
ting analysis (Fig. S3 D, left). Along this line, the lysosome 
inhibitor  chloroquine  induced  the  cytosolic  accumulation  of 
FGF-activated FGFR1 (Fig. S3 D, right). In contrast, in cells 
stimulated with FGL or NCAM-Fc, but not with FGF-2, HA-
FGFR1 entered the recycling compartment (Fig. 5 C). We fur-
ther investigated the recycling of HA-FGFR1 by analyzing its 
colocalization with Rab11, a small GTPase involved in receptor 
Figure 3.  FGFR1 is recycled to the cell surface 
upon NCAM stimulation. (A) The internaliza-
tion (+acid wash) and recycling (acid wash) 
of HA-FGFR1 (green) in transfected HeLa cells 
stimulated  with  FGF-2,  FGL,  or  NCAM-Fc 
were monitored as described in Materials and 
methods. Arrows indicate cells with internal-
ized HA-FGFR1. Asterisks indicate cells where 
HA-FGFR1 recycled back to the cell surface. 
Bar, 10 µm. (B, left) Lysates from HeLa cells 
stimulated with FGF-2, FGL, or NCAM-Fc for 
the indicated time intervals in the presence of 
cycloheximide were immunoblotted for FGFR1 
using tubulin as loading control. The presence 
of  a  doublet  in  lysates  from  cycloheximide-
treated cells might reflect the accumulation of 
an immature FGFR1 form as a consequence 
of the protein synthesis block. (right) Densito-
metric quantitation of FGFR1 in cells stimulated 
as described for the left panel. Data refer to 
the ratio between FGFR1 and tubulin for each 
time point. (C) Surface-biotinylated HeLa cells 
were stimulated with FGF-2 (left) or FGL (right).   
The  rate  of  FGFR1  degradation  and  recy-
cling (expressed as a percentage of internal-
ized receptor) was determined as described 
in  Materials  and  methods.  The  blots  show   
the  results  of  a  representative  experiment. 
Graphs show the means ± SD from three inde-
pendent experiments.JCB • VOLUME 187 • NUMBER 7 • 2009   1106
A and B; and Videos 1–4). Both the covered distance and the 
speed of migrating cells were enhanced by NCAM-derived li-
gands (Fig. 7, A and B). Similar results were obtained with a 3D 
assay for cell migration based on modified Boyden chambers, 
with  FGL  and  NCAM-Fc  inducing  the  migration  of  HeLa 
(Fig. 7 C) and L cells (Fig. S4 B and not depicted), whereas 
FGF-2 failed to do so. In contrast, FN2-Fc did not promote 
cell migration (Fig. 7 C), supporting the key role of NCAM 
interaction with FGFR. Along the same line, NCAM-induced 
cell migration was abolished by either a pretreatment of cells 
with PD173074 (Fig. 7 C) or by the transfection with dn-FGFR1 
(Fig. 7 D). The compound AG1478, a chemical inhibitor of 
EGF receptor (EGFR), showed no effect on FGL-induced cell 
migration, whereas it blocked the migration of EGF-stimulated 
cells (Fig. S4 D), thus supporting the specificity of the NCAM 
interaction with FGFR. Moreover, PP1, SU6656, dn-Src, and 
PD98059 repressed NCAM-induced cell migration (Fig. 7 C 
and Fig. S4 E), which indicated the requirement for both Src 
and Erk1/2/ activity.
In agreement with our previous results (Francavilla et al., 
2007), FGF-2 exerted a strong proliferative effect on both HeLa 
and L cells. In contrast, FGL had no impact on cell proliferation 
(Fig. 7 F and Fig. S4 C), confirming previous observations with 
NCAM-Fc (Francavilla et al., 2007). Thus, NCAM and FGF 
elicit distinct, FGFR-mediated cellular responses in both epi-
thelial cells and fibroblasts, with NCAM promoting cell migra-
tion and FGF inducing cell proliferation.
Based on the promigratory activity of NCAM and on the 
stabilization (and thus recycling) of FGFR1, we verified whether 
NCAM-induced  migration  requires  its  ability  to  promote 
FGFR1 recycling. To this goal, HeLa cells were transfected 
with dn-Rab11, which blocks the recycling pathway (Ren et al., 
1998). Indeed, HA-FGFR1 recycling was no longer observed in 
NCAM-stimulated  HeLa  cells  transfected  with  dn-Rab11, 
whereas it was not affected in cells expressing wild-type Rab11 
(Fig. 8 A). In agreement with this, dn-Rab11 caused the reten-
tion of internalized HA-FGFR1 in early endosomes (Fig. S5 A). 
To confirm the role of Rab11 in FGFR1 recycling, the expres-
sion  of  the  three  members  of  the  Rab11  subfamily,  namely 
Rab11a, Rab11b, and Rab25 (Prekeris, 2003), was ablated by 
using the RNAi technology. Similar to dn-Rab11, the knock-
down of Rab11 genes resulted in the block of HA-FGFR1 recy-
cling in FGL-stimulated cells (Fig. 8 B). Thus, we used both the 
ectopic expression of dn-Rab11 and the knockdown of endoge-
nous Rab11 genes to investigate the contribution of Rab11   
GTPases to NCAM–FGFR-dependent cell migration. Although 
dn-Rab11 abrogated the migratory response of HeLa cells to 
FGL (Fig. 8 C, left), it failed to inhibit cell migration in   
response  to  EGF,  which  is  consistent  with  previous  results 
(Palmieri et al., 2006). Analogous results were obtained when 
Rab11 expression was reduced by siRNA (Fig. 8 C, right). Thus, 
the recycling of FGFR1 via Rab11-dependent pathway is a spe-
cific prerequisite for NCAM-stimulated cell migration. In addi-
tion, the inactivation of endogenous Rab11 with either dn-Rab11 
or siRNA-mediated knockdown caused the loss of sustained 
Src activation in response to NCAM stimulation, whereas no 
effect was observed on FGF-2–induced activation of Erk1/2 
no longer observed in NCAM-stimulated cells that were prein-
cubated with Src inhibitors (Fig. 6 A), and the lack of either cell 
surface or cytosolic staining for HA-FGFR1 pointed to receptor 
degradation. Because these findings implicate Src in NCAM-
dependent stabilization of FGFR1, we determined the effect of 
inhibiting Src on the recruitment of Cbl to FRS-2 upon FGFR 
stimulation with FGF-2 versus FGL. Intriguingly, in PP1- or 
SU6656-treated cells, Cbl formed a complex with FRS-2 even 
upon FGL stimulation (Fig. 6 B). This resulted in FGL promot-
ing FGFR1 ubiquitination to a level comparable with FGF-2 
(Fig. S4 A). Thus, the stabilization and recycling of FGFR ob-
served upon NCAM stimulation implicates an active role of Src 
in preventing the association of Cbl with FRS-2 and the con-
sequent ubiquitination of FGFR1.
NCAM stimulates cell migration, which 
requires FGFR1 recycling
The dichotomy in FGFR signaling and trafficking induced by 
NCAM versus FGF raised the possibility that the two ligands 
elicit  different  FGFR-mediated  cellular  responses.  To  verify 
this hypothesis, we focused on cell migration and proliferation, 
two processes linked with FGFR function (Boilly et al., 2000). 
Monolayer-wounding assays combined with time-lapse video 
microscopy revealed that both FGL and NCAM-Fc promoted 
the migration of HeLa cells, whereas FGF-2 did not (Fig. 7,   
Figure 4.  Differential effect of NCAM and FGF on Cbl-mediated ubiq-
uitination of FGFR1 and the association of Cbl with FRS-2. (A) Lysates 
(3 mg) from HA-FGFR1–transfected HeLa cells stimulated for 10 min with   
FGF-2 or FGL were immunoprecipitated (IP) with anti-HA and immuno-
blotted for ubiquitin (top) followed by immunoblotting for HA (bottom). 
Mock-transfected cells stimulated with FGF-2 were used as negative control.   
(B) Lysates (1 mg) from HeLa cells stimulated for 10 min with FGF-2 or FGL 
were immunoprecipitated with antibodies against FRS-2 and immuno-
blotted for Cbl (top) followed by immunoblotting for FRS-2 (bottom).1107 NCAM induces cell migration via FGFR1 recycling • Francavilla et al.
transfected with wild-type Cbl (Fig. 9 B). Notably, the expres-
sion of dn-Cbl enabled FGF-2 to induce HeLa cell migration, 
although not to the same extent as FGL (Fig. 9 C). Furthermore, 
under these conditions, FGF-2 stimulated sustained Src activa-
tion to a similar level as FGL (Fig. S5 E). Thus, the inhibition of 
Cbl-dependent ubiquitination and degradation of FGFR1 was 
sufficient to switch the functional properties of FGF-2, enabling 
it to mimic NCAM-induced cell migration and sustained signal-
ing. This implies that the biological activity of FGFR1 is strictly 
dependent on its stability and trafficking. However, although 
interfering with FGFR1 degradation resulted in a migratory 
response to FGF-2, the blockade of FGFR1 recycling with 
dn-Rab11 (Fig. S5 F) did not confer proliferative function to 
NCAM (Fig. 9 D). This suggests that additional events are re-
quired to trigger the FGFR1-mediated signaling cascade that 
underlies the proliferative response.
Discussion
The functional cross talk between NCAM and FGFR signaling 
in neurons has long been described (Williams et al., 1994). 
However, the molecular aspects of the interaction between the 
two molecules and, more importantly, the cellular response elic-
ited by this interaction in nonneural cells, have remained elu-
sive. This study shows that NCAM acts as a noncanonical ligand 
for FGFR and stimulates an FGFR-mediated cellular response 
that is remarkably distinct from that elicited by FGF. In particu-
lar, NCAM promotes sustained FGFR signaling and cell migra-
tion, which are two processes that require NCAM-dependent 
recycling of endocytic FGFR1 to the cell surface (whereas the 
receptor is degraded upon FGF stimulation). The dichotomy 
(Fig. 8, D and E). To further validate and extend these findings, 
FGFR1 recycling was inhibited by two additional approaches, 
namely cell pretreatment with monensin (Mitchell et al., 2004) 
and a temperature shift to 16°C (Ren et al., 1998). Both strate-
gies showed efficient repression of NCAM-dependent recycling 
of HA-FGFR1 (Fig. S5, B and C), and in both cases, FGL was 
no longer able to stimulate cell migration, whereas recycling in-
hibition had no effect on EGF-induced migration (Fig. 8, F and G). 
Furthermore, blocking FGFR1 recycling at 16°C resulted in the   
loss of NCAM-stimulated activation of Src (Fig. S5 D). This 
was  not  caused  by  temperature-dependent  inactivation  of 
FGFR1, as under the same conditions, FGF-2 retained the abil-
ity to induce sustained Erk1/2 phosphorylation (Fig. S5 D). 
Thus,  NCAM-induced,  FGFR1-mediated  signal  transduction 
underlying cell migration relies on the recycling of the receptor. 
Collectively, these results support the notion that NCAM pro-
motes cell migration by favoring a sustained and efficient recy-
cling of internalized FGFR1 to the cell surface.
If the different cellular response to NCAM and FGF de-
pends on the different stability and intracellular fate of FGFR1 
imposed by the two ligands, one should be able to switch FGF 
into an NCAM-like stimulus by modulating FGFR1 stability. 
To verify this hypothesis, HeLa cells expressing a dn version of 
Cbl (Penengo et al., 2006) or wild-type Cbl as a control were 
stimulated with either FGF-2 or FGL. The inhibitory effect of 
dn-Cbl was confirmed by the fact that FGFR1 level was no 
longer reduced after a 120-min treatment with FGF-2 (Fig. 9 A). 
The dn-Cbl–dependent stabilization of FGFR1 resulted in the 
recycling of the receptor to the cell surface even after FGF-2 
stimulation (Fig. 9 B), which is in contrast to the receptor deg-
radation observed in parental HeLa cells (Fig. 3) or in cells 
Figure 5.  Colocalization of HA-FGFR1 with different intracellular markers in FGF and NCAM-stimulated cells. (A–C) HA-FGFR1–transfected HeLa cells 
were incubated with anti-HA antibody (green) and stimulated with FGF-2, FGL, or NCAM-Fc for 10 (A), 30 (C), or 60 min (B). In C, TRITC-Tf (red) was 
added together with the stimuli. After acid wash, cells were stained with anti-EEA1 (A) or anti–LAMP-2 (B) antibodies (red) as indicated. (D) HeLa cells 
cotransfected with HA-FGFR1 (red) and Rab11-GFP (green) were incubated with anti-HA antibody and stimulated with FGF-2, FGL, or NCAM-Fc for 60 min. 
After acid wash, cells were stained with Cy3-conjugated anti–mouse antibody. Yellow staining indicates the colocalization of HA-FGFR1 with endosomal 
markers. Bar, 10 µm.JCB • VOLUME 187 • NUMBER 7 • 2009   1108
(Lehembre  et  al.,  2008).  Finally,  as  discussed  in  Results, 
NCAM’s ectodomain or fragments thereof are also released by 
certain cell types in vivo as soluble molecules, thus generating 
potential FGFR ligands analogous to NCAM-Fc and FGL. The 
oligomeric (FGL) or dimeric (NCAM-Fc) state of NCAM frag-
ments  are  also  likely  to  mimic  physiological  conditions,  as 
NCAM is known to oligomerize by means of cis-homophilic 
interactions (Kiselyov et al., 2005).
The  stimulation  of  FGFR  with  soluble  NCAM  under-
scores  the  importance  of  trans-interactions  between  the  two 
molecules, as it would occur upon contact between NCAM- and 
FGFR-expressing cells or upon binding of shed extracellular 
domains of NCAM to cell surface FGFR. Nevertheless, the   
detection of NCAM–FGFR complexes on the surface of sin-
gle cells (Cavallaro et al., 2001; Sanchez-Heras et al., 2006; 
Francavilla et al., 2007) indicates that the two proteins can also 
with FGF-induced response did not depend on the ligand con-
centration used in the experiments (unpublished data).
To  perform  a  direct  comparison  with  the  extracellular, 
soluble factor FGF-2, most of the experiments described in 
this  study  were  conducted  using  either  the  FGL  peptide  or 
NCAM-Fc, namely soluble versions of NCAM-derived ligands. 
Despite NCAM acting mainly as a cell surface molecule, there 
is  evidence  indicating  that  FGL  and  NCAM-Fc  recapitulate 
physiological activities of membrane-associated NCAM, thus 
supporting the biological relevance of our observations. First, 
soluble NCAM fragments mimicked cell surface NCAM in 
inducing FGFR-dependent matrix adhesion in different cell types 
(Cavallaro et al., 2001; this study). Second, in line with our 
findings on NCAM-Fc and FGL as promigratory factors, mem-
brane NCAM induces cell migration in neurons (Maness and 
Schachner, 2007) and during epithelial–mesenchymal transition 
Figure 6.  Src inhibition blocks the recycling 
of FGFR1 and promotes the association of Cbl 
with  FRS-2  in  NCAM-stimulated  cells.  (A) 
HeLa  cells  stimulated  with  FGF-2  or  FGL  in 
the presence of DMSO (top), PP1 (middle), or 
SU6656 (bottom) were processed as for Fig. 
3 A. Asterisk marks a cell where HA-FGFR1 
recycled back to the cell surface. Bar, 10 µm. 
(B) HeLa cells were treated with DMSO (left), 
PP1 (middle), or SU6656 (right) before stimu-
lation with either FGF-2 or FGL for 10 min. 
Cell  extracts  were  immunoprecipitated  (IP) 
with anti–FRS-2 antibody and immunoblotted 
for Cbl (top) followed by immunoblotting for 
FRS-2 (bottom).1109 NCAM induces cell migration via FGFR1 recycling • Francavilla et al.
FGFR1,  impacting  on  ligand-dependent  signaling  (Suyama   
et al., 2002; Bryant et al., 2005). Unlike cadherins, the clustering 
of integrins does stimulate ligand-independent activation of RTKs 
(including EGFR, VEGFR, and PDGF receptor) as a result of the 
cis-interactions between integrins and RTKs themselves (Walker 
et al., 2005). Because NCAM-Fc is expected to act as a dimer (as 
a result of spontaneous Fc dimerization) and the FGL peptide 
was used in its dendrimeric form (Kiselyov et al., 2003), both 
molecules could induce FGFR1 activation by clustering, which 
is similar to cis-interacting integrins.
The molecular basis of the divergence between NCAM- 
and FGF-induced FGFR signaling remains elusive and could 
entail different mechanisms. For example, the two molecules 
could  promote  the  autophosphorylation  of  different  FGFR’s   
tyrosine residues and, therefore, the activation of different dock-
ing sites for the specific effectors. Also, it remains to be clari-
fied whether NCAM induces the recruitment of the receptor to 
engage in cis-interactions. Although we did not detect signifi-
cant differences in signaling or cell matrix adhesion elicited by 
transmembrane NCAM versus soluble NCAM-Fc, cis- and 
trans-interactions between NCAM and FGFR could induce a 
different spectrum of FGFR-mediated cellular responses.
NCAM is unlikely to exert its FGFR-stimulating role by 
enhancing the function of endogenous FGFs given that, on one 
hand, it does not bind to FGF-2 and, on the other hand, NCAM 
actually inhibits the binding of FGF-2 to FGFR (Francavilla 
et al., 2007). These observations, combined with the evidence of 
a physical interaction between NCAM and FGFR (Kos and Chin, 
2002; Kiselyov et al., 2003; Christensen et al., 2006; this study), 
point to NCAM-autonomous stimulation of FGFR activity. Thus, 
the mechanism whereby NCAM regulates FGFR signaling is re-
markably different from that of other adhesion molecules, which 
instead affect the interaction of FGF with its receptor. For exam-
ple, N- and E-cadherin regulate FGF-induced endocytosis of 
Figure  7.  NCAM induces cell migration via 
FGFR1,  Src,  and  Erk1/2,  whereas  FGF  pro-
motes  cell  proliferation.  (A)  Monolayers  of 
HeLa cells were scratch wounded as described 
in Materials and methods and left untreated 
(control)  or  stimulated  with  FGF-2,  FGL,  or 
NCAM-Fc.  Time-lapse  microscopy  was  per-
formed as described in Materials and meth-
ods.  Images  were  taken  from  Videos  1–4. 
Colored lines show five representative tracks 
of single cells. Plots in the right column show 
the trajectories of 45 individually tracked cells 
over the 24-h period (see Materials and meth-
ods).  Values  are  expressed  in  micrometers. 
Bar, 30 µm. (B) Mean distance covered (top) 
and velocity (bottom) of cells stimulated with 
the different ligands. Data represent the mean   
± SEM from 45 individually tracked cells from 
three independent experiments. (C) HeLa cells 
stimulated with FGF-2, FGL, NCAM-Fc, FN2-Fc,   
or Fc were subjected to migration assays in 
modified  Boyden  chambers  (see  Materials 
and methods). FGL stimulation was also per-
formed  in  the  presence  of  PD173074,  PP1, 
or PD98059. (D) HeLa cells transfected with 
an empty vector (mock) or with Myc-tagged 
dn-FGFR1  (transfection  efficiency  was  nearly 
100%;  not  depicted)  were  stimulated  with   
either FGF-2 or FGL and subjected to migration 
assay as for C. (E) HeLa cells were subjected 
to cell proliferation assay in the presence of   
FGF-2 or FGL as described in Materials and 
methods. (C–E) Data represent the mean ± SEM 
from at least three independent experiments. 
*, P < 0.005 relative to untreated cells.JCB • VOLUME 187 • NUMBER 7 • 2009   1110
Figure 8.  Inhibition of FGFR1 recycling represses NCAM-induced cell migration. (A) HeLa cells cotransfected with HA-FGFR1 (red) and either Rab11-
GFP or dn-Rab11–GFP (green) were processed as for Fig. 3 A. Arrowheads indicate the colocalization of Rab11-GFP with HA-FGFR1 (yellow staining), 
whereas arrows indicate the lack of colocalization of HA-FGFR1 with dn-Rab11–GFP. Asterisk indicates a Rab11-GFP–expressing cell with recycled HA-
FGFR1, whereas # shows a dn-Rab11–GFP-expressing cell with no recycling of HA-FGFR1. (B) HeLa cells were transfected with control siRNA (top) or with 
a mixture of siRNA targeting the Rab11 family (bottom) before transfection with HA-FGFR1 (green) and processing as for Fig. 3 A. Arrows indicate cells 
transfected with anti-Rab11 siRNA with no recycling of HA-FGFR1 upon FGL stimulation, whereas the asterisk shows a control cell where HA-FGFR1 has 
recycled to the cell surface. Bars, 10 µm. (C, left) HeLa cells transfected with either Rab11-GFP or dn-Rab11–GFP were stimulated with FGF-2, FGL, or EGF, 
and the migration of GFP-positive cells in modified Boyden chambers was measured. (right) HeLa cells were transfected with either control or anti-Rab11 
siRNA and stimulated and subjected to migration assay as described for the left panel. *, P < 0.005 relative to cells transfected with either Rab11-GFP 
(left) or control siRNA (right) and stimulated with FGL. (D) HeLa cells transfected with either Rab11-GFP or dn-Rab11–GFP were stimulated with FGL (top) 
or FGF-2 (bottom) for the indicated time lengths. Lysates from FGL-stimulated cells were immunoblotted for phospho-Src and total Src, whereas lysates from 1111 NCAM induces cell migration via FGFR1 recycling • Francavilla et al.
Our study revealed the tight connection between recycling 
of FGFR1 to the plasma membrane and NCAM-induced cell 
migration. Interestingly, transmembrane NCAM itself under-
goes endocytosis and recycling in neurons (Diestel et al., 2007). 
Although the biological significance of these processes remains 
elusive, it is tempting to speculate that NCAM could act as a 
carrier for other proteins and in particular for FGFR, thus favor-
ing their recycling to the cell surface. Despite the copious 
evidence that endocytosis is used by cells to propagate RTK-
mediated  signaling  from  endosomal  compartments  (Hoeller   
et al., 2005), very few studies have focused on RTK recycling 
(Marmor and Yarden, 2004), and little information is available 
on its biological significance. Recycling of EGFR and PDGF/
VEGFR is critical for the spatial redistribution of RTK signal-
ing during the directional migration of border cells in Drosoph-
ila melanogaster (Jékely et al., 2005). The role of recycling in 
ensuring localized signaling during cell migration has also been 
reported for the small GTPase Rac (Palamidessi et al., 2008) 
and for integrins (for review see Caswell and Norman, 2008). 
Future  research  should  clarify  whether  FGFR1  recycling  in 
NCAM-stimulated migratory cells is necessary to restrict re-
ceptor localization to specific membrane compartments or if it 
rather represents a mechanism to avoid degradation and ensure 
the sustained signaling required to maintain a motile phenotype. 
In this context, it appears that the duration of NCAM-dependent 
FGFR signaling is critical to confer a migratory phenotype to 
cells. This was further confirmed by our observation that pre-
venting FGFR1 ubiquitination and degradation, thus promoting 
its recycling, was sufficient to confer promigratory activity to 
FGF-2. Thus, the cellular response to FGF-2 is dictated by the 
stability of FGFR1, which in turn affects the duration of down-
stream signaling. In agreement with this view, forcing the sus-
tained activation of FGFR2 induces epithelial to mesenchymal 
transition and cellular invasion (Xian et al., 2007).
Our results on the NCAM–FGFR1 interplay that induces 
recycling-dependent cell migration have broad physiopatholog-
ical  implications.  For  example,  NCAM-dependent  sustained 
activation and recycling of FGFR are very likely to underlie ax-
onal growth, a process that requires an intact FGFR signaling 
downstream of NCAM both in vitro and in vivo (Saffell et al., 
1997). NCAM knockout mice exhibit various developmental 
and  behavioral  defects,  including  the  impaired  migration  of 
neuronal precursors to the olfactory bulb (Cremer et al., 1994). 
Our findings imply that these defects might depend on the dis-
ruption of promigratory FGFR signaling upon loss of NCAM. 
In this context, NCAM-deficient mice exhibit a depression-like 
phenotype that is reverted by the treatment with FGL (Aonurm-
Helm et al., 2008). These findings support the physiological rel-
evance of the NCAM–FGFR interaction for brain development 
specific  membrane  compartments  where  the  repertoire  of 
adaptors/effectors would be different from that normally affected 
by FGF stimulation.
The dichotomy in FGFR signaling between NCAM and 
FGF is best exemplified by the pathway of Erk1/2 activation 
(Ras-dependent for FGF and Ras-independent and Src-dependent 
for NCAM) and by the differential involvement of Shc and 
Src downstream of FGFR (specifically activated by FGF and 
NCAM, respectively). Src-mediated activation of Erk1/2 can 
result from integrin signaling through focal adhesion kinase 
(Mitra and Schlaepfer, 2006). Because NCAM–FGFR signal-
ing stimulates 1-integrin function in pancreatic -tumor cells 
(Cavallaro et al., 2001), NCAM-induced activation of FGFR 
could trigger an integrin–FAK–Src–Erk1/2 pathway. This model 
would be supported by the observation that, similar to NCAM, 
integrin-mediated activation of Erk1/2 is independent of Ras 
(Chen et al., 1996), although this issue is still controversial 
(Clark and Hynes, 1996).
The divergence between NCAM and FGF signaling is ac-
companied by a dramatic difference in the intracellular traffick-
ing of FGFR1, with FGF inducing the classical route of rapid 
internalization  and  lysosomal  degradation,  whereas  NCAM 
promotes FGFR1 stabilization and recycling to the cell surface. 
We have provided evidence that NCAM stimulation uncouples 
receptor  internalization  from  ubiquitination,  most  likely  be-
cause  NCAM  does  not  induce  the  recruitment  of  Cbl  to   
FRS-2, which is required for FGFR1 ubiquitination and deg-
radation  upon  FGF  stimulation  (Wong  et  al.,  2002).  Recent 
studies showed that preventing ubiquitination targets FGFR1 to 
recycling endosomes instead of lysosomes (Haugsten et al., 2008), 
further supporting the view that this is the mechanism under-
lying NCAM-dependent recycling of FGFR1. The sharp dichot-
omy in the intracellular fate of FGFR1 after FGF versus NCAM 
stimulation is likely determined by Src activity. Indeed, Src pre-
vents the association of Cbl with FRS-2 and, thus, the ubiqui-
tination of FGFR1, thus accounting for the lack of receptor 
degradation and for its recycling to the cell surface. However, 
our unpublished results ruled out the possibility that Src induces 
the phosphorylation of Cbl in NCAM-stimulated cells, thus 
hindering its recruitment to FRS-2 (unpublished data). It is 
conceivable that NCAM stimulation promotes Src-dependent 
phosphorylation of one or more substrates that in turn interfere 
with the formation of the Cbl–FRS-2 complex, which is a 
hypothesis that deserves further investigation. In parallel with 
Src-dependent FGFR recycling, we also observed that the sus-
tained activation of Src induced by NCAM requires FGFR recy-
cling itself. This points to a mutual regulation between the two 
events as a key step in the cellular response elicited by the 
NCAM–FGFR interplay.
FGF-2–stimulated cells were immunoblotted for phospho-Erk1/2 and total Erk1/2. (E) HeLa cells transfected with either control or anti-Rab11 siRNA were 
stimulated with FGF-2 or FGL for the indicated time lengths. Knockdown was verified by immunoblotting for Rab11a/Rab11b and for Rab25 using vinculin 
as a loading control (left). Lysates from stimulated cells were immunoblotted for activated Src or Erk1/2 as described for D. (F) HeLa cells were cultured 
at 37 or 16°C, stimulated with FGF-2, FGL, or EGF, and subjected to migration assay in modified Boyden chambers. *, P < 0.005 relative to cells grown 
at 37°C and stimulated with FGL. (G) HeLa cells stimulated with FGF-2, FGL, or EGF in the presence of either DMSO or monensin (10 or 100 µM) were 
subjected to migration assay in modified Boyden chambers. *, P < 0.005 relative to DMSO-treated cells stimulated with FGL. Data represent the mean ± 
SEM from three independent experiments.
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acting as an unconventional ligand, stimulates a signaling cas-
cade remarkably distinct from that induced by FGF. Further-
more, our experiments revealed that NCAM induces sustained 
FGFR activation by uncoupling receptor internalization from 
ubiquitination and promoting Rab11-dependent recycling of the 
receptor, and this results in cell migration. Besides uncovering 
a further level of complexity in the regulation of RTK activity, 
our data could contribute to elucidate the pathogenesis of those 
disorders  characterized  by  dysregulated  function  of  NCAM 
and/or FGFR.
Materials and methods
Reagents
The following commercial reagents were used: FGF-2 (PeproTech), EGF   
(Inalco),  the  MEK  inhibitor  PD98059,  the  inhibitor  of  transport  to 
plasma membrane monensin, the protein synthesis inhibitor cycloheximide 
and plasticity. Notably, although NCAM knockout mice are via-
ble and reach adulthood, the transgenic expression of the soluble 
NCAM’s ectodomain in the same mice results in dominant em-
bryonic lethality (Rabinowitz et al., 1996). This implies that 
NCAM heterophilic interactions require a tight regulation during 
embryonic development, and we speculate that excessive stimu-
lation of FGFR by soluble NCAM contributes to the phenotype 
of mutant mice. Finally, the aberrant expression of NCAM is a 
hallmark of various neoplastic diseases (Zecchini and Cavallaro, 
2008), and the sustained activation of FGFR (as found in various 
cancer types; Acevedo et al., 2009) might underlie a proinvasive 
role of NCAM during tumor progression. This hypothesis is sup-
ported by our recent data implicating the NCAM–FGFR inter-
play as a causal factor in ovarian carcinoma (unpublished data).
In summary, we have unraveled a novel mechanism of 
FGFR activation involving the interaction with NCAM that, 
Figure  9.  Inhibition of Cbl-mediated FGFR1 
degradation results in FGF-2–induced cell mi-
gration. (A, left) Lysates from HeLa cells stably 
transfected with Cbl or dn-Cbl were immuno-
blotted for Cbl using tubulin as loading control. 
(right) Transfected cells were stimulated with 
FGF-2 or FGL in the presence of cycloheximide 
for the indicated time intervals followed by lysis 
and immunoblotting for FGFR1 using tubulin as 
loading control. NT, not transfected. (B) HeLa 
cells stably expressing either wild-type Cbl or 
dn-Cbl were transfected with HA-FGFR1. Cells 
were  incubated  with  anti-HA  antibody  and 
stimulated with either FGF-2 or FGL. Cells were 
processed as for Fig. 3 A. Asterisks mark cells 
where HA-FGFR1 recycled back to the cell sur-
face. Bar, 10 µm. (C) Hela cells stably trans-
fected with either wild-type Cbl (gray bars) or 
dn-Cbl  (black  bars)  and  nontransfected  cells 
(white  bars)  were  stimulated  with  FGF-2  or 
FGL before migration assay in modified Boy-
den chambers. (D) HeLa cells transfected with 
an empty vector (open symbols) or with GFP-
tagged dn-Rab11 (closed symbols) were serum 
starved and stimulated with FGF-2 or FGL for 
the indicated time intervals. Cell proliferation 
was determined as described in Materials and 
methods. *, P < 0.005 relative to untreated 
cells.  Data  represent  the  mean  ±  SEM  from 
three independent experiments.1113 NCAM induces cell migration via FGFR1 recycling • Francavilla et al.
time points with 40 µg/ml FGL, 20 µg/ml NCAM-Fc or FN2-Fc, or 20 
ng/ml FGF-2. A mutated version of FGL unable to interact with FGFR 
(Kiselyov et al., 2003) was used in most assays as a control for FGL, and 
consistently showed no effect. When needed, cells were preincubated for 
2  h  with  chemical  inhibitors  at  the  following  concentrations:  100  nM 
PD173074, 25 µM PD98059, 20 µM PP1, 270 nM SU6656, 0.5 µM 
AG1478, 25 µM cycloheximide, and 10 or 100 µM monensin. Control 
cells were preincubated with DMSO alone. After stimulation, cell extraction 
and  immunoblotting  were  performed  as  described  previously  (Francavilla   
et al., 2007). Each experiment was repeated at least three times.
Cell surface biotinylation and immunoprecipitation
Internalization and recycling of FGFR1 were quantitatively evaluated as 
described previously (Fabbri et al., 1999; Lampugnani et al., 2006). In 
brief, cells were plated at 80% confluence on 100-mm-diameter dishes and 
incubated on ice for 60 min in the presence of 0.5 mg/ml thiol-cleavable 
sulfo-NHS-S-S-biotin (Thermo Fisher Scientific). After washing, labeled cells 
were incubated at 37°C for the indicated time periods in the presence of 
FGF-2 or FGL to allow internalization. Cells were incubated on ice twice 
for 20 min with 45 mM GSH (glutathione; EMD), a membrane-nonpermeable 
reducing agent, to remove the biotin label from surface proteins. Free 
sulfo-reactive groups were quenched with iodoacetamide (Sigma-Aldrich). 
Total labeling was determined in samples not treated with GSH, whereas 
background values were obtained from samples not subjected to incuba-
tion at 37°C.
Immunoprecipitation of FGFR1 from cell extracts was performed as 
described previously (Cavallaro et al., 2001) using anti–FGFR1 (C15).   
After SDS-PAGE, immunoprecipitates were probed with HRP-conjugated 
streptavidin (to visualize biotinylated FGFR1) followed by stripping and   
immunoblotting  for  total  FGFR1.  Densitometric  analysis  was  performed 
with the ImageJ software (National Institutes of Health). Internalization was 
calculated as a percentage of the total amount of labeled receptor.
FGFR1 recycling and degradation (Fig. 3 C) was determined as de-
scribed previously (Fabbri et al., 1999). In brief, cells were labeled with 
sulpho-NHS-SS-biotin (as described in the previous paragraph), and inter-
nalization was allowed for 30 min at 37°C in the presence of the stimuli. 
Cells were treated with GSH (as described in the previous paragraph) to 
remove the label from the residual cell surface receptor. The internalized 
fraction was chased by reincubation at 37°C for the indicated time points 
in duplicate samples. One sample (Fig. 3 C, +GSH) was treated with GSH 
to determine the amount of FGFR1 that recycled back to the plasma mem-
brane, whereas the other sample (GSH) was left untreated to determine 
the total level of labeled receptor at each time point. The samples were 
subjected to FGFR1 immunoprecipitation and immunoblotting as described 
in the previous paragraph. In GSH samples, HRP-conjugated streptavidin 
recognized residual biotinylated FGFR1 after incubation at 37°C without 
GSH treatment (i.e., internalized + recycled  degraded). In +GSH sam-
ples, HRP-conjugated streptavidin recognized residual biotinylated FGFR1 
after incubation at 37°C and GSH treatment (i.e., internalized  recycled 
 degraded). FGFR1 degradation was calculated by subtracting the den-
sitometric value of residual biotinylated receptor in GSH samples from 
the total pool of internalized receptor. FGFR1 recycling was calculated by 
subtracting both the degradation value and the value of residual biotinyl-
ated receptor in +GSH samples from the total pool of internalized receptor 
(Lampugnani et al., 2006). Values represent the means ± SD from at least 
three independent experiments.
Cell proliferation assays
Cells were seeded in triplicate on 24-well plates at 8 × 10
3 cells/well, 
serum starved overnight, and treated for 1–4 d with FGF-2 or FGL replen-
ished every 24 h. At each time point, viable cells were counted using the 
Trypan blue exclusion method, and the ratio with nonstimulated cells at 
time 0 was determined for each time point. Values represent the means ± 
SEM from at least three independent experiments performed in triplicate.
Cell migration
Time-lapse  video  microscopy  was  performed  as  described  previously 
(White et al., 2007; Palamidessi et al., 2008) with slight modifications. In 
brief, confluent monolayers of serum-starved HeLa cells were wounded 
with a plastic pipette tip to induce migration into the wound. Cells were in-
cubated in serum-free, Hepes-buffered L15 medium containing the different 
stimuli and placed on the stage of an inverted motorized microscope (IX81; 
Olympus) in a cage incubator (Okolab) at 37°C. Phase-contrast images 
were collected with a 10× NA 0.3 UPlan lens (FLN; Olympus) every 15 
min over a 24-h period using a camera (Orca-AG; Hamamatsu Photonics) 
and the cell^R software (Olympus). Videos were generated using the 
(Sigma-Aldrich), and the Src inhibitors PP1 and SU6656 (EMD). The FGFR 
inhibitor PD173074 (Skaper et al., 2000) was provided by Pfizer. The 
EGFR inhibitor AG1478 was obtained from Sigma-Aldrich.
The following antibodies were used: rabbit anti–phospho-Akt and 
anti-Akt; mouse anti–phospho-Erk1/2, rabbit anti-phospho–FRS-2, rabbit 
anti–phospho-Src (recognizing the activated form of most Src kinases), rab-
bit  anti-phospho–PLC-,  anti–phospho-Shc,  and  anti-Shc  (Cell  Signaling 
Technology);  rabbit  anti-Erk1/2  and  mouse  antitubulin  and  antivinculin 
(Sigma-Aldrich); mouse anti-HA (clone F7; used in immunoprecipitation 
and Western blot analysis); rabbit anti-FGFR1, anti-FGFR2, anti-FGFR3, 
anti-FGFR4, rabbit anti–FRS-2, mouse anti-NCAM (clone 123C3), anti-Src 
kinases, anti-GFP, antiubiquitin, and anti-Rab25; goat anti-EEA1 (Santa Cruz 
Biotechnology, Inc.); mouse anti–PLC-, anti-Cbl, and anti-phosphotyrosine 
(BD); mouse anti-HA tag (used in immunofluorescence; HA.11; Covance); 
and rabbit anti-Rab11, cross-reacting with both Rab11a and Rab11b 
(Invitrogen). Rabbit anti–LAMP-2 was provided by G. Griffiths (Cambridge 
Institute for Medical Research, Cambridge, England, UK).
The Myc-tagged scFv against FGFR1 was isolated and used in   
immunoblotting as described previously (Francavilla et al., 2007). Peroxidase-
conjugated streptavidin was obtained from Jackson ImmunoResearch Labo-
ratories), and TRITC-conjugated Tf (TRITC-Tf) was obtained from Invitrogen. 
The FGL peptide from the second FNIII module of NCAM and its mutated 
version, FGLmut, which carries two alanine substitutions that abolish its binding 
to FGFR (Kiselyov et al., 2003), were provided by ENKAM Pharmaceuticals. 
Peptides were synthesized as dendrimers, with four peptides attached to a 
three-lysine backbone (Kiselyov et al., 2003).
Expression vectors
The  pIg3  vectors  containing  the  cDNA  for  the  ectodomain  of  human 
NCAM, either full-length or deleted of the second FNIII repeat (FN2), 
fused to the Fc fragment of human IgG (NCAM-Fc and FN2-Fc, respec-
tively), were provided by L. Needham (Duke University, Durham, NC). The 
cDNA for full-length, transmembrane NCAM-140 was subcloned into a 
pRc/CMV vector. The pSecTag vector encoding the HA-Myc-His–tagged 
ectodomain of human NCAM was provided by D. Sjostrand (Stockholm, 
Sweden).  The  pRK5tkNEO  vector  encoding  the  ectodomain  of  human 
FGFR1 fused to human Fc was provided by A. Gurney (Genentech). These 
vectors were used to transiently transfect HEK293 cells, and the recombi-
nant proteins were purified from the conditioned medium of transfected 
cells by affinity chromatography. The pDisplay vector encoding N-terminally 
HA-tagged FGFR1 (Zhang et al., 2001) was provided by G. David   
(Leuven, Belgium). The cDNA for dn-Ras (N17V), generated by J.S. Gutkind, 
was provided by G. Scita (IFOM, Milan, Italy). The cDNA for Rab11-GFP 
and dn-Rab11 (S25N)-GFP were obtained from F. Senic-Matuglia (IFOM, 
Milan, Italy) and B. Goud (Institut Curie, Paris, France). The cDNA encod-
ing dn-FGFR1 (Werner et al., 1993) was subcloned into the pMex-neo vec-
tor. dn-Src (K295R and Y527F), generated by J. Brugge, was provided by 
M. Sallese (Mario Negri Sud, Santa Maria Imbaro, Italy).
Cell lines and transfection
Mouse fibroblastic L cells and human epithelial HeLa cells were cultured in 
DME supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 
U/ml penicillin, and 100 µg/ml streptomycin at 37°C in a humidified incu-
bator with 5% CO2 (Francavilla et al., 2007; Palamidessi et al., 2008). 
HeLa cells were transfected using Lipofectamine (Invitrogen) according to 
the manufacturer’s instructions, and all of the assays were performed 36 h 
after transfection. HeLa cells stably transfected with wild-type or dn-Cbl 
(Penengo et al., 2006) were provided by S. Polo (Milan, Italy).
RNAi
Double-stranded,  validated  Stealth  siRNA  oligonucleotides  targeting 
Rab11a  (5-GGAGCUGUAGGUGCCUUAUUGGUUU-3)  and  Rab11b 
(5-GACGACGAGUACGACUACCUAUUCA-3;  Arnaud  et  al.,  2007) 
were purchased from Invitrogen. A pool of two siRNA duplexes against 
Rab25 (also known as Rab11c; 5-CAUGCUCGUGGGUAACAAA-3 and 
5-CUUCAUGCCCUAUCACAAA-3) was purchased from Santa Cruz Bio-
technology, Inc. Cells were transfected with a mixture of all Rab11-target-
ing siRNAs as previously described (Francavilla et al., 2007). An siRNA 
duplex against mouse NCAM (Francavilla et al., 2007) was used as a 
negative control. Silencing of gene expression was monitored by immuno-
fluorescence and immunoblotting of cell lysates with antibodies against 
Rab11 (cross reacting with both a and b) or Rab25.
Cell stimulation and immunoblotting
Cells were cultured in 6-well plates in complete medium and serum starved 
overnight in serum-free medium. Cells were stimulated for the indicated JCB • VOLUME 187 • NUMBER 7 • 2009   1114
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ImageJ software for image analysis. Cell trajectories were determined 
using the manual tracking plugin of ImageJ. This procedure generated x and 
y coordinates for the center of each cell at each time point. Trajectories 
were reconstructed according to the recorded data. The distance covered 
by each cell and the migration speed were extracted from the track plots. 
45 cells from three independent experiments were analyzed for each con-
dition, and data are expressed in micrometers as mean ± SEM.
Boyden chamber
Cell migration was measured using a two-chamber Transwell system (5-µm 
pores; Costar). The top side of the filter was coated with polylysine. 40,000 
serum-starved cells were seeded in the top well of Transwell in the presence 
of stimuli and, when indicated, of inhibitors. 400 µl of complete medium 
was placed in the bottom chamber as chemoattractant. Migration was 
allowed for 16 (L cells) or 24 h (HeLa cells) at 37 or16°C. Cells remaining 
on the top surface of filters were scraped off. Cells on the bottom side were 
fixed with paraformaldehyde and stained with DAPI. Cells were counted in 
10 random fields per filter using a microscope (Biosystem BX61; Olympus) 
with a 20× NA 0.7 Plan Apo lens equipped with a camera (F-View II; 
Olympus) and the analySIS software (Soft Imaging System GmbH). Results 
represent mean ± SEM of at least three independent experiments for each 
cell types performed in triplicate.
Immunofluorescence
Immunofluorescence staining of live cells and postfixation were performed 
as described previously (Di Guglielmo et al., 2003; Martínez-Arca et al., 
2005). In brief, HA-FGFR1–transfected HeLa cells were incubated on ice 
with 10 µg/ml anti-HA antibody for 45 min with gentle agitation. We veri-
fied that the binding of the antibody did not activate HA-FGFR1 signaling 
in untreated cells. Moreover, the antibody did not induce HA-FGFR1 inter-
nalization (Fig. 3 A, control). After adding FGF-2, NCAM-Fc, or FGL, cells 
were incubated at 37°C for different time periods. At each time point, non-
permeabilized cells were either fixed to visualize the receptor on the cell 
surface or acid washed in ice-cold buffer (50 mM glycine, pH 2.5) to re-
move surface-bound antibody. Cells were fixed and permeabilized to visu-
alize the internalized receptor. Samples treated with TRITC-Tf (added to the 
medium at a final concentration of 50 µg/ml) were kept in the dark. Finally, 
to detect HA-FGFR1, cells were stained with Alexa Fluor 488–conjugated 
donkey  anti–mouse  (Jackson  ImmunoResearch  Laboratories).  Coverslips 
were mounted in 10% Mowiol (Kuraray Europe GmbH), and images 
were collected at room temperature using a microscope (Biosystem BX61) 
with a 100× 1.4 NA Plan Apo oil lens. For each time point and each treat-
ment, the presence and localization (i.e., cell surface vs. internalized) of 
HA-FGFR1 were assessed in seven randomly chosen fields. Approximately 
100 cells per treatment were analyzed for each time point from three inde-
pendent experiments. The ratio between the number of HA-FGFR1–positive 
cells and total cells (corresponding to DAPI-stained nuclei) was determined 
and referred to the values obtained at time 0. For colocalization experi-
ments,  cells  were  permeabilized  with  0.02%  saponin  (Sigma-Aldrich), 
treated with primary antibodies for 1 h at 37°C, and stained with Alexa 
Fluor 488–conjugated donkey anti–mouse together with CY3-conjugated 
donkey anti–rabbit or donkey anti–goat secondary antibodies.
When cells were transfected with GFP-containing plasmids, a CY3-
conjugated goat anti–mouse secondary antibody was used. Images were 
acquired at room temperature from single confocal planes using an acousto-
optical beam splitter confocal microscope (TCS SP2; Leica) and illumination 
from a 405-nm laser diode, a 488-nm argon laser, a 561-nm solid-state 
laser, and a 633-nm HeNe laser. We used a 63× 1.40 NA Plan Apo oil 
lens (HCX; Leica) and a 3.7× zoom. Images were acquired using confocal 
software (Leica) and processed with Photoshop (version CS3; Adobe).
Online supplemental material
Fig. S1 shows that NCAM binds directly to FGFR1 and promotes FGFR-
mediated cell adhesion. Fig. S2 shows that NCAM and FGF stimulate distinct 
signaling pathways downstream of FGFR. Fig. S3 shows the characteriza-
tion and quantification of FGFR1 internalization, degradation, and recy-
cling upon stimulation with FGL or FGF-2. Fig. S4 shows that Src inhibition 
results in FGL-induced ubiquitination of FGFR1 and that NCAM induces 
L cell migration via FGFR1, Src, and Erk1/2. Fig. S5 shows that FGR1 recy-
cling is required for NCAM-induced cell migration. Videos 1–4 show the 
migration of HeLa cells either unstimulated or stimulated with FGF-2, FGL, 
or NCAM-Fc. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200903030/DC1.
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